<SEC-DOCUMENT>0001157523-19-001535.txt : 20190718
<SEC-HEADER>0001157523-19-001535.hdr.sgml : 20190718
<ACCEPTANCE-DATETIME>20190718063023
ACCESSION NUMBER:		0001157523-19-001535
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20190718
FILED AS OF DATE:		20190718
DATE AS OF CHANGE:		20190718

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		19960396

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a52015074.htm
<DESCRIPTION>AURINIA PHARMACEUTICALS INC. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 6.0.0.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-weight: bold;">Washington, D.C. 20549</div>
    <div>&#160; <br>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">FORM 6-K<br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"> </div>
    <div>&#160; <br>
    </div>
    <div style="text-align: center; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER<br>
      PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE<br>
      SECURITIES EXCHANGE ACT OF 1934</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Dated July 18, 2019</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Commission File Number 001-36421</div>
    <div>&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">AURINIA PHARMACEUTICALS INC.</div>
    <div style="text-align: center; font-weight: bold;">(Exact name of Registrant as specified in its charter)</div>
    <div>&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">N/A</div>
    <div style="text-align: center; font-weight: bold;">(Translation of Registrant&#8217;s Name)</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">#1203-4464 Markham Street<br>
      Victoria, British Columbia<br>
      V8Z7X8<br>
      (250) 708-4272<br>
      (Address and telephone number of registrant&#8217;s principal executive offices)</div>
    <div>&#160;</div>
    <div>&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="margin-left: 21.6pt;"> <br>
    </div>
    <div style="margin-left: 21.6pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
    <div>&#160;</div>
    <div style="text-align: center;">Form 20-F&#160; &#9744;&#160;&#160;&#160;&#160;&#160; Form 40-F &#9746;</div>
    <div>&#160;</div>
    <div style="margin-left: 21.6pt;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
    <div>&#160;</div>
    <div style="margin-left: 21.6pt;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 21.6pt;">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
      Securities Exchange Act of 1934.</div>
    <div>&#160;</div>
    <div style="text-align: center;">Yes&#160;&#9746;&#160;&#160;&#160;&#160;&#160; No&#160; &#9744;</div>
    <div>&#160;</div>
    <div style="text-indent: 21.6pt; margin-right: 14.4pt;">This Form 6-K is hereby filed and incorporated by reference in the registrant&#8217;s Registration Statement on Form F-10 (File No. 333-222413).</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 21.6pt; margin-right: 3.6pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
      authorized.</div>
    <div style="text-align: justify; text-indent: 21.6pt; margin-right: 3.6pt;"> <br>
    </div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" id="zbeee2b5335d3480b90386279553ee454" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 50%;">
              <div>Dated: July 18, 2019 <br>
              </div>
            </td>
            <td style="width: 4%;">
              <div>&#160;</div>
            </td>
            <td style="width: 46%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 4%;">
              <div>&#160;</div>
            </td>
            <td style="width: 46%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td colspan="2" rowspan="1">
              <div><font style="font-weight: bold;">Aurinia Pharmaceuticals Inc.</font> <br>
              </div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50%;">&#160;</td>
            <td colspan="2" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 4%; padding-bottom: 2px;">
              <div>By: <br>
              </div>
            </td>
            <td style="width: 46%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Peter S. Greenleaf <br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 4%;">
              <div>&#160;</div>
            </td>
            <td style="width: 46%;">
              <div>Name: Peter S. Greenleaf <br>
              </div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50%;">&#160;</td>
            <td rowspan="1" style="width: 4%;">&#160;</td>
            <td rowspan="1" style="width: 46%;">Title: Chief Executive Officer <br>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div>&#160;</div>
    <div style="text-align: center;"><font style="font-weight: bold;">EXHIBIT INDEX </font><br>
    </div>
    <div><font style="font-weight: bold;"><br>
      </font><font style="text-indent: 0px; font-size: 5.1pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="da24ea5c484e42c7a9c71c3208d3d334" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

        <tr>
          <td style="width: 10%; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold;">Exhibit</font> <br>
          </td>
          <td style="width: 5%; padding-bottom: 2px;">&#160;</td>
          <td style="width: 85%; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold;">Description of Exhibit</font> <br>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; text-indent: 9pt;"><a href="a52015074_ex991.htm#Exhibit991">99.1</a> <br>
          </td>
          <td style="width: 5%;">&#160;</td>
          <td style="width: 85%; text-indent: 9pt;"><a href="a52015074_ex991.htm#Exhibit991">News Release - Aurinia Announces Further Strengthening of the Senior
              Management Team.</a> <br>
          </td>
        </tr>

    </table>
    <br>
    <div style="margin-right: 14.4pt;">Exhibit 99.1 included with this report on Form 6-K is hereby incorporated by reference as exhibits to the Registration Statement on Form F-10 of Aurinia Pharmaceuticals Inc. (File No. 333-222413), as amended or
      supplemented.</div>
    <div><br>
    </div>
    <br>
  </div>
  <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a52015074_ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 6.0.0.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;"><a name="Exhibit991"><!--Anchor--></a>Exhibit 99.1</font><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div><font style="font-weight: bold;"> </font>
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position:inside;FONT-SIZE: 14pt;"> <b>Aurinia Announces Further Strengthening of the Senior Management Team </b> </h1>
      <div class="bw-release-subhead">
        <p style="text-align: center; list-style-position:inside;"><b> - Max Donley appointed EVP, Internal Operations and Strategy - <br>
            - Glenn Schulman appointed SVP, Corporate Communications and Investor Relations - </b></p>
      </div>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>VICTORIA, British Columbia--(BUSINESS WIRE)--July 18, 2019--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP) (the &#8220;Company&#8221;), a late-stage clinical biopharmaceutical company with ongoing research in lupus nephritis (&#8220;LN&#8221;), today announced
            the appointments of Mr. Max Donley as Executive Vice President of Internal Operations and Strategy and Dr. Glenn Schulman as Senior Vice President of Corporate Communications and Investor Relations. </p>
          <p> &#8220;It is a pleasure to welcome Max and Glenn to the team at this critical juncture for Aurinia. As we continue to build and expand the organization, and prepare for the potential U.S. commercialization of voclosporin, their respective talents
            complement the team already in place, helping to scale the organization and ensure we maintain open communication with all of our stakeholders,&#8221; commented Peter S. Greenleaf, President and Chief Executive Officer of Aurinia. </p>
          <p> Mr. Donley commented, &#8220;This is an exciting time for Aurinia, and for the future treatment landscape for LN. In parallel to preparing for the clinical and regulatory requirements of filing a NDA to the FDA, I look forward to spearheading
            infrastructure growth necessary to support the potential commercialization of voclosporin and maturation of Aurinia into a vertically integrated commercial biopharmaceutical company.&#8221; </p>
          <p> <b>Max Donley, MBA <br>
              <i>Executive Vice President, Internal Operations and Strategy <br>
              </i></b>Mr. Donley most recently led Human Resources, Information Technology and Facilities at Senseonics. Prior to that, Mr. Donley was Executive Vice President of Global Human Resources, Information Technology, and Corporate Strategy at
            Sucampo Pharmaceuticals until its acquisition in February 2018. Prior to that, Mr. Donley served as Executive Vice President, Human Resources and Corporate Affairs at MedImmune, where he provided business-integrated leadership and delivered
            professional tools, programs and services to optimize MedImmune&#8217;s human capital investments worldwide. </p>
          <p> Mr. Donley received his BA from University of Michigan and his MBA from the George Mason University. </p>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> <b>Glenn Schulman, PharmD, MPH <br>
              <i>Senior Vice President, Corporate Communications and Investor Relations <br>
              </i></b>Glenn Schulman is a healthcare professional with nearly twenty years of advising biotech and life science companies. Prior to joining Aurinia, Dr. Schulman led Corporate Communications and Investor Relations at Achillion
            Pharmaceuticals, Inc. (NASDAQ: ACHN). Prior to Achillion, Dr. Schulman held positions of increasing responsibility at CuraGen Corp. where he was ultimately responsible for all aspects of corporate and medical communications, investor and public
            relations. </p>
          <p> Dr. Schulman received his BS Pharmacy from Philadelphia College of Pharmacy, Doctor of Pharmacy degree from Rutgers, Ernest Mario School of Pharmacy, and completed a post-doctoral fellowship at Memorial Sloan-Kettering Cancer Center. Dr.
            Schulman received his MPH, Health Management, from Yale University. </p>
          <p> <b>About Aurinia</b> </p>
          <p> Aurinia Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The
            Company is currently developing an investigational drug, for the treatment of Lupus Nephritis, Focal Segmental Glomerulosclerosis and Dry Eye Syndrome. The Company&#8217;s head office is in Victoria, British Columbia and focuses its development
            efforts globally. For further information, see our website at www.auriniapharma.com. </p>
          <p> <b>About Voclosporin</b> </p>
          <p> Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (&#8220;CNI&#8221;) with clinical data in over 2,600 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual
            mechanism of action. By inhibiting calcineurin, voclosporin blocks IL-2 expression and T-cell mediated immune responses and stabilizes the podocyte in the kidney. It has been shown to have a more predictable pharmacokinetic and pharmacodynamic
            relationship (potentially requires no therapeutic drug monitoring), an increase in potency (vs cyclosporin), and an improved metabolic profile compared to legacy CNIs. Aurinia anticipates that upon regulatory approval, patent protection for
            voclosporin will be extended in the United States and certain other major markets, including Europe and Japan, until at least October 2027 under the Hatch-Waxman Act and comparable laws in other countries and until April 2028 with anticipated
            pediatric extension. Further, the new Notice of Allowance is expected to result in the issuance of a U.S. patent with a term extending to December 2037. If the FDA approves the use of voclosporin for LN and the label for such use follows the
            dosing protocol under the Notice of Allowance, the issuance of this patent will expand the scope of intellectual property protection for voclosporin to December 2037. </p>
          <p> <b>About VOS</b> </p>
          <p> Voclosporin ophthalmic solution (&#8220;VOS&#8221;) is an aqueous, preservative free nanomicellar solution intended for use in the treatment of DES. A Phase 2a study was recently completed with results released in January of 2019. Previously, a Phase 1
            study with healthy volunteers and patients with DES was also completed as were studies in rabbit and dog models. VOS has IP protection until 2031.</p>
          <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div id="DSPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <p> <b>Forward-Looking Statements</b> </p>
          Certain statements made in this press release may constitute forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable United States securities law. These
          forward-looking statements or information include but are not limited to statements or information with respect to: Aurinia&#8217;s anticipation that upon regulatory approval, patent protection for voclosporin will be extended in the United States and
          certain other major markets, including Europe and Japan, until at least October 2027 under the Hatch-Waxman Act and comparable laws in other countries and until April 2028 with anticipated pediatric extension; that the new Notice of Allowance is
          expected to result in the issuance of a U.S. patent with a term extending to December 2037; that if the FDA approves the use of voclosporin for LN and the label for such use follows the dosing protocol under the Notice of Allowance, the issuance
          of this patent will expand the scope of intellectual property protection for voclosporin to December 2037; Aurinia&#8217;s ongoing commitment to drive shareholder value through the advancement and commercialization of voclosporin and to maintain an
          active dialogue with its investment community as it continues to execute on the Company&#8217;s strategy.
          <p> It is possible that such results or conclusions may change based on further analyses of these data. Words such as &#8220;anticipate&#8221;, &#8220;will&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;target&#8221;, &#8220;plan&#8221;, &#8220;goals&#8221;, &#8220;objectives&#8221;, &#8220;may&#8221; and other
            similar words and expressions, identify forward-looking statements. We have made numerous assumptions about the forward-looking statements and information contained herein, including among other things, assumptions about: Aurinia being able to
            extend and protect its patents on terms acceptable to Aurinia, Aurinia successfully completing its clinical trials, Aurinia receiving regulatory approval on terms acceptable to Aurinia, and Aurinia having sufficient funds on hand to complete
            its trials and operations as currently planned. </p>
          <p> Even though the management of Aurinia believes that the assumptions made, and the expectations represented by such statements or information are reasonable, there can be no assurance that the forward-looking information will prove to be
            accurate. </p>
          <p> Forward-looking information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aurinia to be materially different
            from any future results, performance or achievements expressed or implied by such forward-looking information. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may
            vary materially from those described in forward-looking statements or information. Such risks, uncertainties and other factors include, among others, the following: Aurinia not being able to extend or fully protect its patent portfolio for
            voclosporin, Aurinia not obtaining necessary regulatory approval, negative results from clinical trials, and cash outlays being higher than currently planned. </p>
          <p> Although we have attempted to identify factors that would cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actual results,
            performances, achievements or events to not be as anticipated, estimated or intended. Also, many of the factors are beyond our control. There can be no assurance that forward-looking statements or information will prove to be accurate, as
            actual results and future events could differ materially from those anticipated in such statements. Accordingly, you should not place undue reliance on forward-looking statements or information. </p>
          <p> Except as required by law, Aurinia will not update forward-looking information. All forward-looking information contained in this press release is qualified by this cautionary statement. Additional information related to Aurinia, including a
            detailed list of the risks and uncertainties affecting Aurinia and its business can be found in Aurinia&#8217;s most recent Annual Information Form available by accessing the Canadian Securities Administrators&#8217; System for Electronic Document Analysis
            and Retrieval (SEDAR) website at www.sedar.com or the U.S. Securities and Exchange Commission&#8217;s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar. </p>
          <p> <i>We seek Safe Harbor</i><br>
          </p>
        </div>
        <br>
        <div style="font-weight: bold;" class="bw-release-table-js bw-release-story">Contacts</div>
        <div class="bw-release-contact">
          <p></p>
          <p> Investors &amp; Media <br>
            Glenn Schulman, PharmD, MPH <br>
            SVP, Corp Comm &amp; IR <br>
            gschulman@auriniapharma.com </p>
        </div>
      </div>
    </div>
    <font style="font-weight: bold;"> </font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
